MedTrace Logo

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

NCT03802344 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 498

Last updated 2020-12-16

Study results available
· View outcomes & findings →

Summary

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

MC2-01 cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

DRUG

Cal/BDP combination

Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%

DRUG

Vehicle

Vehicle cream

Sponsors & Collaborators

  • MC2 Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2019-10-02
Completion
2019-10-02
FDA Drug
Yes

Countries

  • Czechia
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802344 on ClinicalTrials.gov